Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase II Study of R-CHOP and Ibritumomab Tiuxetan (Zevalin) for Elderly Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Authors not listed

Memorial Sloan Kettering Cancer Center · 2003

Abstract

RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab and combination chemotherapy with yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab and combination chemotherapy with yttrium Y 90 ibritumomab tiuxetan in treating older patients who have B-cell lymphoma that has not been previously treated.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-19 MST

Cite this

APA
Anonymous. (2003). A Phase II Study of R-CHOP and Ibritumomab Tiuxetan (Zevalin) for Elderly Patients With Previously Untreated Diffuse Large B-Cell Lymphoma. <em>Memorial Sloan Kettering Cancer Center</em>. https://clinicaltrials.gov/study/NCT00058422
Vancouver
Anonymous. A Phase II Study of R-CHOP and Ibritumomab Tiuxetan (Zevalin) for Elderly Patients With Previously Untreated Diffuse Large B-Cell Lymphoma. Memorial Sloan Kettering Cancer Center. 2003.
BibTeX
@misc{anon2003APhase, title = {A Phase II Study of R-CHOP and Ibritumomab Tiuxetan (Zevalin) for Elderly Patients With Previously Untreated Diffuse Large B-Cell Lymphoma}, author = {Anonymous}, journal = {Memorial Sloan Kettering Cancer Center}, year = {2003}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings